Skip to main content

Biomarkers for Early Detection of Cardiotoxicity

Edited by:

Steven Lipshultz, MD, University at Buffalo, United States of America
Joseph Carver, MD, University of Pennsylvania and Abramson Cancer Center, United States of America
Giorgio Minotti, MD, University and Fondazione Policlinico Campus Bio-Medico, Italy
 

Submission Status: Open   |   Submission Deadline: 30 September 2025


Cardio-Oncology is calling for submissions to our Collection on 'Biomarkers for Early Detection of Cardiotoxicity.' 

This Collection seeks to highlight cutting-edge research on the identification and validation of biomarkers that can predict cardiotoxicity at an early stage.

About the Collection

Cardio-Oncology is calling for submissions to our Collection on 'Biomarkers for Early Detection of Cardiotoxicity.' 

This Collection seeks to highlight cutting-edge research on the identification and validation of biomarkers that can predict cardiotoxicity at an early stage. Early detection of cardiotoxicity is crucial for preventing irreversible heart damage in patients undergoing chemotherapy or those exposed to environmental and genetic risk factors. We welcome original research, reviews, and clinical studies that explore the discovery, validation, and application of biomarkers in cardiotoxicity. 

Submissions are encouraged on the following topics:

1. Novel biomarkers for cardiotoxicity
2. Non-invasive and minimally invasive diagnostic tools
3. Biomarker validation and clinical utility
4. Biomarkers in chemotherapy-induced cardiotoxicity
5. Genetic and epigenetic factors influencing cardiotoxicity
6. Translational research and personalized medicine
7. Multi-biomarker approaches
8. Mechanisms underlying cardiotoxicity


Image credit: © ArtemisDiana / Stock.adobe.com

  1. Trastuzumab is an effective treatment for HER2-positive cancers that has known cardiotoxic properties. Discovering biomarkers that assess cardiotoxicity risk before trastuzumab therapy is essential for protect...

    Authors: Jamila Mammadova, Alicia Richards, Adriana Gonzalez-Torriente, Evan R. Adler, Rachel J. Cruz, Stefanie Palfi, Dae Hyun Lee, Christine Sam, Mohammed Al-Jumayli, Anders Berglund, Jong Y Park, Mohammed Alomar and Jacob K. Kresovich
    Citation: Cardio-Oncology 2025 11:44
    Content type: Research Published on:

  2. Anthracyclines are essential in early breast cancer chemotherapy but pose long-term cardiotoxicity risks.

    Authors: Nattaya Poovorawan, Thiti Susiriwatananont, Chinachote Teerapakpinyo, Pajaree Chariyavilaskul, Piyada Sitthideatphaiboon, Luxica Jarutasnangkul, Monravee Tumkosit, Pairoj Chattranukulchai, Nonthikorn Theerasuwipakorn, Chatchawit Aporntewan, Shanop Shuangshoti, Sopark Manasnayakorn, Chanida Vinayanuwattikun, Yongkasem Vorasettakarnkij and Virote Sriuranpong
    Citation: Cardio-Oncology 2025 11:39
    Content type: Research Published on:

  3. Cardiotoxicity has become a major concern in cancer patients, especially those with lung cancer, as anti-tumor therapies can significantly affect patient survival and quality of life. This study aims to develo...

    Authors: Yumin Wang, Chunyan Huan, Huijuan Pu, Guodong Wang, Yan Liu, Xiuli Zhang, Chengyang Li, Jie Liu, Wanling Wu and Defeng Pan
    Citation: Cardio-Oncology 2025 11:32
    Content type: Research Published on:

Submission Guidelines

Back to top

This Collection welcomes submission of Research Articles and Reviews. Should you wish to submit a different article type, please read our submission guidelines to confirm that type is accepted by the journal. 

Articles for this Collection should be submitted via our submission system, Snapp. Please, select the appropriate Collection title “Biomarkers for Early Detection of Cardiotoxicity" under the “Details” tab during the submission stage. Articles will undergo the journal’s standard peer-review process and are subject to all the journal’s standard policies. Articles will be added to the Collection as they are published.

The Editors have no competing interests with the submissions which they handle through the peer-review process. The peer-review of any submissions for which the Editors have competing interests is handled by another Editorial Board Member who has no competing interests.